NT5C2

Overview

NT5C2 encodes a cytosolic 5’-nucleotidase implicated in thiopurine resistance in relapsed ALL. In the corpus it appears as a relapse-associated gene in infant ALL PMID:25730765.

Alterations observed in the corpus

  • Relapse-associated mutations identified in infant ALL PMID:25730765.
  • NT5C2 D407Y pharmacogenomic variant in relapsed B-cell ALL (BLL) conferring resistance to nucleoside-analog therapy; informed salvage regimen choice in a pediatric precision-oncology cohort PMID:28007021

Cancer types (linked)

Co-occurrence and mutual exclusivity

  • Not reported in this corpus.

Therapeutic relevance

  • Relevance to thiopurine-based maintenance therapy resistance is implied by relapse enrichment PMID:25730765.

Open questions

  • Whether NT5C2 mutations are selected during maintenance therapy in infant MLL-R ALL specifically PMID:25730765.

Sources

This page was processed by entity-page-writer on 2026-04-08. - PMID:28007021

This page was processed by entity-page-writer on 2026-05-15.